About us

SkyePharma has been established in 1996 and is a leading speciality drug delivery company with a proven range of oral and inhalation technologies.

SkyePharma strives to deliver a clinical benefit for patients by using its multiple delivery technologies to create enhanced versions of existing pharmaceutical products as well as products incorporating new chemical entities.

Combining established pre-clinical, clinical and regulatory expertise with the capability to formulate and manufacture drugs, both for clinical studies and commercial sale, SkyePharma identifies and develops potential new therapeutic products for out-licensing as well as working with partners to develop their concepts through to marketable products.

There are twelve products approved in the areas of oral, inhalation and topical delivery and additional products submitted for approval that incorporate the Group’s proven proprietary technologies. The Group’s products are marketed throughout the world by leading pharmaceutical companies.

With lab-scale and full scale GMP manufacturing capabilities, the Group offers development and commercial scale production for both oral and inhalation compounds. We have established an excellent track record for partnering and working closely with companies of all sizes.

SkyePharma also offers formulation and technology capabilities, particularly in the areas of inhaled and controlled oral drug delivery, to other pharmaceutical companies on a partnered development and licensing basis.

With headquarters in London, UK, SkyePharma has its main research and development centre in Muttenz, near Basel in Switzerland, and its main manufacturing operations in Lyon, France.

SkyePharma's shares trade on the London Stock Exchange under the symbol SKP.

SkyePharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 105 Piccadilly, London, W1J 7NJ, United Kingdom